{"id":"W4319008670","doi":"10.1161/str.54.suppl_1.tp15","title":"Abstract TP15: Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion","year":2023,"lang":"en","type":"article","venue":"Stroke","topic":"Neurological Disease Mechanisms and Treatments","field":"Neuroscience","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Stroke (engine); Modified Rankin Scale; Neuroprotection; Clinical trial; Clinical endpoint; Placebo; Internal medicine; Brain ischemia; Glutamate receptor; Anesthesia; Ischemia; Ischemic stroke; Receptor; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004420365,0.001160276,0.001054997,0.0003278974,0.0004830578,0.001423216,0.001614716,0.002501248,0.01152873],"category_scores_gemma":[0.002346792,0.0002988139,0.0009162605,0.0003659828,0.0007955741,0.0008381899,0.0004334623,0.003063289,0.0035545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007879325,"about_ca_system_score_gemma":0.002345761,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005586711,"about_ca_topic_score_gemma":0.001463322,"domain_scores_codex":[0.999193,0.0003938796,0.00007261377,0.0001110176,0.0001171825,0.000112244],"domain_scores_gemma":[0.9982664,0.0002422646,0.0002353896,0.0001219535,0.000237808,0.0008962736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6353831,0.01348029,0.003994555,0.002175934,0.001096694,0.000934927,0.0001890836,0.001051743,0.0308615,0.002119985,0.0462885,0.2624237],"study_design_scores_gemma":[0.710335,0.2270705,0.009242955,0.000411214,0.0006683076,0.0006736951,0.00004059984,0.00119035,0.005959507,0.001011333,0.04333968,0.0000569513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7734095,0.03556495,0.01247843,0.03017395,0.00714424,0.06299508,0.03247882,0.001537048,0.04421804],"genre_scores_gemma":[0.8415021,0.01164496,0.01559835,0.02524912,0.003706921,0.04426751,0.02340434,0.0002249066,0.03440178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01152873,"threshold_uncertainty_score":0.03856742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02486623123188128,"score_gpt":0.2742290142557937,"score_spread":0.2493627830239124,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}